<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37337289</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2047-9158</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jun</Month><Day>19</Day></PubDate></JournalIssue><Title>Translational neurodegeneration</Title><ISOAbbreviation>Transl Neurodegener</ISOAbbreviation></Journal><ArticleTitle>Update on the pathological roles of prostaglandin E<sub>2</sub> in neurodegeneration in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>32</StartPage><MedlinePgn>32</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">32</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40035-023-00366-w</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by selective degeneration of upper and lower motor neurons. The pathogenesis of ALS remains largely unknown; however, inflammation of the spinal cord is a focus of ALS research and an important pathogenic process in ALS. Prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) is a major lipid mediator generated by the arachidonic-acid cascade and is abundant at inflammatory sites. PGE<sub>2</sub> levels are increased in the postmortem spinal cords of ALS patients and in ALS model mice. Beneficial therapeutic effects have been obtained in ALS model mice using cyclooxygenase-2 inhibitors to inhibit the biosynthesis of PGE<sub>2</sub>, but the usefulness of this inhibitor has not yet been proven in clinical trials. In this review, we present current evidence on the involvement of PGE<sub>2</sub> in the progression of ALS and discuss the potential of microsomal prostaglandin E synthase&#xa0;(mPGES) and the prostaglandin receptor E-prostanoid (EP)&#xa0;2 as therapeutic targets for ALS. Signaling pathways involving prostaglandin receptors mediate toxic effects in the central nervous system. In some situations, however, the receptors mediate neuroprotective effects. Our recent studies demonstrated that levels of mPGES-1, which catalyzes the final step of PGE<sub>2</sub> biosynthesis, are increased at the early-symptomatic stage in the spinal cords of transgenic ALS model mice carrying the G93A variant of superoxide dismutase-1. In addition, in an experimental motor-neuron model used in studies of ALS, PGE<sub>2</sub> induces the production of reactive oxygen species and subsequent caspase-3-dependent cytotoxicity through activation of the EP2 receptor. Moreover, this PGE<sub>2</sub>-induced EP2 up-regulation in motor neurons plays a role in the death of motor neurons in ALS model mice. Further understanding of the pathophysiological role of PGE<sub>2</sub> in neurodegeneration may provide new insights to guide the development of novel therapies for ALS.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nango</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Laboratory of Pharmacology, School of Pharmacy, Nihon University, 7-7-1 Narashinodai, Funabashi-Shi, Chiba, 274-8555, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsuruta</LastName><ForeName>Komugi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Laboratory of Pharmacology, School of Pharmacy, Nihon University, 7-7-1 Narashinodai, Funabashi-Shi, Chiba, 274-8555, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyagishi</LastName><ForeName>Hiroko</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Laboratory of Pharmacology, School of Pharmacy, Nihon University, 7-7-1 Narashinodai, Funabashi-Shi, Chiba, 274-8555, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aono</LastName><ForeName>Yuri</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, School of Dentistry at Matsudo, Nihon University, 2-870-1 Sakaechonishi, Matsudo-Shi, Chiba, 271-8587, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saigusa</LastName><ForeName>Tadashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, School of Dentistry at Matsudo, Nihon University, 2-870-1 Sakaechonishi, Matsudo-Shi, Chiba, 271-8587, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kosuge</LastName><ForeName>Yasuhiro</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-7513-5132</Identifier><AffiliationInfo><Affiliation>Laboratory of Pharmacology, School of Pharmacy, Nihon University, 7-7-1 Narashinodai, Funabashi-Shi, Chiba, 274-8555, Japan. kosuge.yasuhiro@nihon-u.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Transl Neurodegener</MedlineTA><NlmUniqueID>101591861</NlmUniqueID><ISSNLinking>2047-9158</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>K7Q1JQR04M</RegistryNumber><NameOfSubstance UI="D015232">Dinoprostone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015232" MajorTopicYN="N">Dinoprostone</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">E-prostanoid receptor</Keyword><Keyword MajorTopicYN="N">Microsomal prostaglandin E synthetase-1</Keyword><Keyword MajorTopicYN="N">Motor neuron death</Keyword><Keyword MajorTopicYN="N">Prostaglandin E2</Keyword></KeywordList><CoiStatement>YK received grants from REFINE HOLDINGS CO., LTD, and the other authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>20</Day><Hour>1</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>19</Day><Hour>23</Hour><Minute>38</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37337289</ArticleId><ArticleId IdType="pmc">PMC10278279</ArticleId><ArticleId IdType="doi">10.1186/s40035-023-00366-w</ArticleId><ArticleId IdType="pii">10.1186/s40035-023-00366-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bruijn LI, Miller TM, Cleveland DW. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci. 2004;27:723&#x2013;749. doi: 10.1146/annurev.neuro.27.070203.144244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.27.070203.144244</ArticleId><ArticleId IdType="pubmed">15217349</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraiuolo L, Kirby J, Grierson AJ, Sendtner M, Shaw PJ. Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat Rev Neurol. 2011;7(11):616&#x2013;630. doi: 10.1038/nrneurol.2011.152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2011.152</ArticleId><ArticleId IdType="pubmed">22051914</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362(6415):59&#x2013;62. doi: 10.1038/362059a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/362059a0</ArticleId><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan S, Orrell RW. Pathogenesis of amyotrophic lateral sclerosis. Br Med Bull. 2016;119(1):87&#x2013;97. doi: 10.1093/bmb/ldw026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bmb/ldw026</ArticleId><ArticleId IdType="pubmed">27450455</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, et al. Motor neuron degeneration in mice that express a human Cu. Zn superoxide dismutase mutation Science. 1994;264(5166):1772&#x2013;1775.</Citation><ArticleIdList><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, McGeer EG. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve. 2002 doi: 10.1002/mus.10191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.10191</ArticleId><ArticleId IdType="pubmed">12362410</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekizawa T, Openshaw H, Ohbo K, Sugamura K, Itoyama Y, Niland JC. Cerebrospinal fluid interleukin 6 in amyotrophic lateral sclerosis: immunological parameter and comparison with inflammatory and non-inflammatory central nervous system diseases. J Neurol Sci. 1998;154(2):194&#x2013;199. doi: 10.1016/S0022-510X(97)00228-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(97)00228-1</ArticleId><ArticleId IdType="pubmed">9562310</ArticleId></ArticleIdList></Reference><Reference><Citation>Mennini T, Giordano L, Mengozzi M, Ghezzi P, Tonelli R, Mantegazza R, et al. Increased IL-8 levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Eur J Inflamm. 2009;7(1):39&#x2013;44. doi: 10.1177/1721727X0900700105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1721727X0900700105</ArticleId></ArticleIdList></Reference><Reference><Citation>Italiani P, Carlesi C, Giungato P, Puxeddu I, Borroni B, Boss&#xf9; P, et al. Evaluating the levels of interleukin-1 family cytokines in sporadic amyotrophic lateral sclerosis. J Neuroinflamm. 2014;11:1&#x2013;7. doi: 10.1186/1742-2094-11-94.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-11-94</ArticleId><ArticleId IdType="pmc">PMC4039322</ArticleId><ArticleId IdType="pubmed">24884937</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortarolo M, Lo Coco D, Veglianese P, Vallarola A, Giordana MT, Marcon G, et al. Amyotrophic lateral sclerosis, a multisystem pathology: insights into the role of TNF&#x3b1;. Mediators Inflamm. 2017;2017:2985051. doi: 10.1155/2017/2985051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/2985051</ArticleId><ArticleId IdType="pmc">PMC5610855</ArticleId><ArticleId IdType="pubmed">29081600</ArticleId></ArticleIdList></Reference><Reference><Citation>Lampson LA, Kushner PD, Sobel RA. Major histocompatibility complex antigen expression in the affected tissues in amyotrophic lateral sclerosis. Ann Neurol. 1990;28(3):365&#x2013;372. doi: 10.1002/ana.410280311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410280311</ArticleId><ArticleId IdType="pubmed">2241118</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki S, Shibata N, Komori T, Iwata M. iNOS and nitrotyrosine immunoreactivity in amyotrophic lateral sclerosis. Neurosci Lett. 2000;291(1):44&#x2013;48. doi: 10.1016/S0304-3940(00)01370-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(00)01370-7</ArticleId><ArticleId IdType="pubmed">10962150</ArticleId></ArticleIdList></Reference><Reference><Citation>Dachet F, Liu J, Ravits J, Song F. Predicting disease specific spinal motor neurons and glia in sporadic ALS. Neurobiol Dis. 2019;130(June):104523. doi: 10.1016/j.nbd.2019.104523.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2019.104523</ArticleId><ArticleId IdType="pubmed">31276795</ArticleId></ArticleIdList></Reference><Reference><Citation>Crisafulli SG, Brajkovic S, Cipolat Mis MS, Parente V, Corti S. Therapeutic strategies under development targeting inflammatory mechanisms in amyotrophic lateral sclerosis. Mol Neurobiol. 2018;55(4):2789&#x2013;2813. doi: 10.1007/s12035-017-0532-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-017-0532-4</ArticleId><ArticleId IdType="pubmed">28455693</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Beers DR, Henkel JS, Zhang W, Urushitani M, Julien JP, et al. Extracellular mutant SOD1 induces microglial-mediated motoneuron injury. Glia. 2010;58(2):231&#x2013;243. doi: 10.1002/glia.20919.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.20919</ArticleId><ArticleId IdType="pmc">PMC2784168</ArticleId><ArticleId IdType="pubmed">19672969</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541(7638):481&#x2013;487. doi: 10.1038/nature21029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature21029</ArticleId><ArticleId IdType="pmc">PMC5404890</ArticleId><ArticleId IdType="pubmed">28099414</ArticleId></ArticleIdList></Reference><Reference><Citation>Guttenplan KA, Weigel MK, Adler DI, Couthouis J, Liddelow SA, Gitler AD, et al. Knockout of reactive astrocyte activating factors slows disease progression in an ALS mouse model. Nat Commun. 2020;11(1):1&#x2013;9. doi: 10.1038/s41467-020-17514-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-17514-9</ArticleId><ArticleId IdType="pmc">PMC7385161</ArticleId><ArticleId IdType="pubmed">32719333</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R, Yang B, Zhang D. Activation of interferon signaling pathways in spinal cord astrocytes from an ALS mouse model. Glia. 2011;59(6):946&#x2013;958. doi: 10.1002/glia.21167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.21167</ArticleId><ArticleId IdType="pmc">PMC3077460</ArticleId><ArticleId IdType="pubmed">21446050</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen MD, Julien JP, Rivest S. Induction of proinflammatory molecules in mice with amyotrophic lateral sclerosis: no requirement for proapoptotic interleukin-1&#x3b2; in neurodegeneration. Ann Neurol. 2001;50(5):630&#x2013;639. doi: 10.1002/ana.1256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.1256</ArticleId><ArticleId IdType="pubmed">11706969</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Y, Ripley B, Serada S, Naka T, Fujimoto M. Interleukin-6 deficiency does not affect motor neuron disease caused by superoxide dismutase 1 mutation. PLoS ONE. 2016;11(4):1&#x2013;13. doi: 10.1371/journal.pone.0153399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0153399</ArticleId><ArticleId IdType="pmc">PMC4829212</ArticleId><ArticleId IdType="pubmed">27070121</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortarolo M, Vallarola A, Lidonnici D, Battaglia E, Gensano F, Spaltro G, et al. Lack of TNF-alpha receptor type 2 protects motor neurons in a cellular model of amyotrophic lateral sclerosis and in mutant SOD1 mice but does not affect disease progression. J Neurochem. 2015;135(1):109&#x2013;124. doi: 10.1111/jnc.13154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13154</ArticleId><ArticleId IdType="pubmed">25940956</ArticleId></ArticleIdList></Reference><Reference><Citation>Olesen MN, Wuolikainen A, Nilsson AC, Wirenfeldt M, Forsberg K, Madsen JS, et al. Inflammatory profiles relate to survival in subtypes of amyotrophic lateral sclerosis. Neurol Neuroimmunol Neuroinflamm. 2020;7(3):e697. doi: 10.1212/NXI.0000000000000697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000697</ArticleId><ArticleId IdType="pmc">PMC7136052</ArticleId><ArticleId IdType="pubmed">32123048</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillis JW, Horrocks LA, Farooqui AA. Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders. Brain Res Rev. 2006;52(2):201&#x2013;243. doi: 10.1016/j.brainresrev.2006.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresrev.2006.02.002</ArticleId><ArticleId IdType="pubmed">16647138</ArticleId></ArticleIdList></Reference><Reference><Citation>Almer G, Teismann P, Stevic Z, Halaschek-Wiener J, Deecke L, Kostic V, et al. Increased levels of the pro-inflammatory prostaglandin PGE2 in CSF from ALS patients. Neurology. 2002;58(8):1277&#x2013;1279. doi: 10.1212/WNL.58.8.1277.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.58.8.1277</ArticleId><ArticleId IdType="pubmed">11971099</ArticleId></ArticleIdList></Reference><Reference><Citation>I&#x142;zecka J. Prostaglandin E2 is increased in amyotrophic lateral sclerosis patients. Acta Neurol Scand. 2003;108(2):125&#x2013;129. doi: 10.1034/j.1600-0404.2003.00102.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1600-0404.2003.00102.x</ArticleId><ArticleId IdType="pubmed">12859290</ArticleId></ArticleIdList></Reference><Reference><Citation>Klivenyi P, Kiaei M, Gardian G, Calingasan NY, Beal MF. Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem. 2004;88(3):576&#x2013;582. doi: 10.1046/j.1471-4159.2003.02160.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2003.02160.x</ArticleId><ArticleId IdType="pubmed">14720207</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyagishi H, Kosuge Y, Takano A, Endo M, Nango H, Yamagata-Murayama S, et al. Increased expression of 15-hydroxyprostaglandin dehydrogenase in spinal astrocytes during disease progression in a model of amyotrophic lateral sclerosis. Cell Mol Neurobiol. 2017;37(3):445&#x2013;452. doi: 10.1007/s10571-016-0377-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10571-016-0377-9</ArticleId><ArticleId IdType="pubmed">27140190</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi D, Mouchlis VD, Dennis EA. Omega-3 versus Omega-6 fatty acid availability is controlled by hydrophobic site geometries of phospholipase A2s. J Lipid Res. 2021;63:100113. doi: 10.1016/j.jlr.2021.100113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jlr.2021.100113</ArticleId><ArticleId IdType="pmc">PMC8551542</ArticleId><ArticleId IdType="pubmed">34474084</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricciotti E, Fitzgerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011;31(5):986&#x2013;1000. doi: 10.1161/ATVBAHA.110.207449.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.110.207449</ArticleId><ArticleId IdType="pmc">PMC3081099</ArticleId><ArticleId IdType="pubmed">21508345</ArticleId></ArticleIdList></Reference><Reference><Citation>Peebles RS. Prostaglandins in asthma and allergic diseases. Pharmacol Ther. 2019;193:1&#x2013;19. doi: 10.1016/j.pharmthera.2018.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2018.08.001</ArticleId><ArticleId IdType="pmc">PMC6309751</ArticleId><ArticleId IdType="pubmed">30081047</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanioka T, Nakatani Y, Semmyo N, Murakami M, Kudo I. Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. J Biol Chem. 2000;275(42):32775&#x2013;32782. doi: 10.1074/jbc.M003504200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M003504200</ArticleId><ArticleId IdType="pubmed">10922363</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakobsson PJ, Thor&#xe9;n S, Morgenstern R, Samuelsson B. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci USA. 1999;96(13):7220&#x2013;7225. doi: 10.1073/pnas.96.13.7220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.96.13.7220</ArticleId><ArticleId IdType="pmc">PMC22058</ArticleId><ArticleId IdType="pubmed">10377395</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanikawa N, Ohmiya Y, Ohkubo H, Hashimoto K, Kangawa K, Kojima M, et al. Identification and characterization of a novel type of membrane-associated prostaglandin E synthase. Biochem Biophys Res Commun. 2002;291(4):884&#x2013;889. doi: 10.1006/bbrc.2002.6531.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/bbrc.2002.6531</ArticleId><ArticleId IdType="pubmed">11866447</ArticleId></ArticleIdList></Reference><Reference><Citation>Samuelsson B, Morgenstern R, Jakobsson PJ. Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev. 2007;59(3):207&#x2013;224. doi: 10.1124/pr.59.3.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/pr.59.3.1</ArticleId><ArticleId IdType="pubmed">17878511</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohan S, Ahmad AS, Glushakov AV, Chambers C, Dor&#xe9; S. Putative role of prostaglandin receptor in intracerebral hemorrhage. Front Neurol. 2012 doi: 10.3389/fneur.2012.00145.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2012.00145</ArticleId><ArticleId IdType="pmc">PMC3477820</ArticleId><ArticleId IdType="pubmed">23097645</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiriyama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, Narumiya S. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997;122(2):217&#x2013;224. doi: 10.1038/sj.bjp.0701367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjp.0701367</ArticleId><ArticleId IdType="pmc">PMC1564924</ArticleId><ArticleId IdType="pubmed">9313928</ArticleId></ArticleIdList></Reference><Reference><Citation>Anggard E, Oliw E. Formation and metabolism of prostaglandins in the kidney. Kidney Int. 1981;19(6):771&#x2013;780. doi: 10.1038/ki.1981.79.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.1981.79</ArticleId><ArticleId IdType="pubmed">6790808</ArticleId></ArticleIdList></Reference><Reference><Citation>Jerde TJ, Mellon WS, Fischer SM, Liebert M, Bjorling DE, Nakada SY. Suppression of 15-hydroxyprostaglandin dehydrogenase messenger RNA concentration, protein expression, and enzymatic activity during human ureteral obstruction. J Pharmacol Exp Ther. 2004;309(1):398&#x2013;403. doi: 10.1124/jpet.103.056929.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.103.056929</ArticleId><ArticleId IdType="pubmed">14718596</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SC, Levine L. Prostaglandin metabolism. II. Identification of two 15-hydroxyprostaglandin dehydrogenase types. J Biol Chem. 1975;250(2):548&#x2013;552. doi: 10.1016/S0021-9258(19)41931-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(19)41931-5</ArticleId><ArticleId IdType="pubmed">234431</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarabak J, Fried J. Comparison of substrate specificities of the human placental NAD- and NADP-linked 15-hydroxyprostaglandin dehydrogenases. Prostaglandins. 1979;18(2):241&#x2013;246. doi: 10.1016/0090-6980(79)90109-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0090-6980(79)90109-6</ArticleId><ArticleId IdType="pubmed">42948</ArticleId></ArticleIdList></Reference><Reference><Citation>Yagami T, Koma H, Yamamoto Y. Pathophysiological roles of cyclooxygenases and prostaglandins in the central nervous system. Mol Neurobiol. 2016;53(7):4754&#x2013;4771. doi: 10.1007/s12035-015-9355-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-015-9355-3</ArticleId><ArticleId IdType="pubmed">26328537</ArticleId></ArticleIdList></Reference><Reference><Citation>Almer G, Gu&#xe9;gan C, Teismann P, Naini A, Rosoklija G, Hays AP, et al. Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis. Ann Neurol. 2001;49(2):176&#x2013;185. doi: 10.1002/1531-8249(20010201)49:2&lt;176::AID-ANA37&gt;3.0.CO;2-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1531-8249(20010201)49:2&lt;176::AID-ANA37&gt;3.0.CO;2-X</ArticleId><ArticleId IdType="pubmed">11220737</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasojima K, Tourtellotte WW, McGeer EG, McGeer PL. Marked increase in cyclooxygenase-2 in ALS spinal cord: implications for therapy. Neurology. 2001;57(6):952&#x2013;956. doi: 10.1212/WNL.57.6.952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.57.6.952</ArticleId><ArticleId IdType="pubmed">11571316</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiaei M, Kipiani K, Petri S, Choi DK, Chen J, Calingasan NY, et al. Integrative role of cPLA2 with COX-2 and the effect of non-steriodal anti-inflammatory drugs in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem. 2005;93(2):403&#x2013;411. doi: 10.1111/j.1471-4159.2005.03024.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2005.03024.x</ArticleId><ArticleId IdType="pubmed">15816863</ArticleId></ArticleIdList></Reference><Reference><Citation>Pompl PN, Ho L, Bianchi M, McManus T, Qin W, Pasinetti GM. A therapeutic role for cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. FASEB J. 2003;17(6):725&#x2013;727. doi: 10.1096/fj.02-0876fje.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.02-0876fje</ArticleId><ArticleId IdType="pubmed">12586733</ArticleId></ArticleIdList></Reference><Reference><Citation>Drachman DB, Frank K, Dykes-Hoberg M, Teismann P, Almer G, Przedborski S, et al. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann Neurol. 2002;52(6):771&#x2013;778. doi: 10.1002/ana.10374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10374</ArticleId><ArticleId IdType="pubmed">12447931</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyagishi H, Kosuge Y, Ishige K, Ito Y. Expression of microsomal prostaglandin E synthase-1 in the spinal cord in a transgenic mouse model of amyotrophic lateral sclerosis. J Pharmacol Sci. 2012;118(2):225&#x2013;236. doi: 10.1254/jphs.11221FP.</Citation><ArticleIdList><ArticleId IdType="doi">10.1254/jphs.11221FP</ArticleId><ArticleId IdType="pubmed">22302024</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin JH, Lee YA, Lee JK, Lee YB, Cho W, Im DS, et al. Concurrent blockade of free radical and microsomal prostaglandin e synthase-1-mediated PGE 2 production improves safety and efficacy in a mouse model of amyotrophic lateral sclerosis. J Neurochem. 2012;122(5):952&#x2013;961. doi: 10.1111/j.1471-4159.2012.07771.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2012.07771.x</ArticleId><ArticleId IdType="pubmed">22537108</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Lee E, Song W, Ricciotti E, Rader DJ, Lawson JA, et al. Microsomal prostaglandin E synthase-1 deletion suppresses oxidative stress and angiotensin II-induced abdominal aortic aneurysm formation. Circulation. 2008;117(10):1302&#x2013;1309. doi: 10.1161/CIRCULATIONAHA.107.731398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.107.731398</ArticleId><ArticleId IdType="pubmed">18285567</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda-Matsuo Y, Miyata H, Mizoguchi T, Ohama E, Naito Y, Uematsu S, et al. Microsomal prostaglandin E synthase-1 is a critical factor in dopaminergic neurodegeneration in Parkinson&#x2019;s disease. Neurobiol Dis. 2018;2019(124):81&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">30423474</ArticleId></ArticleIdList></Reference><Reference><Citation>Tada S, Okuno T, Shimizu M, Sakai Y, Sumi-Akamaru H, Kinoshita M, et al. Single injection of sustained-release prostacyclin analog ONO-1301-MS ameliorates hypoxic toxicity in the murine model of amyotrophic lateral sclerosis. Sci Rep. 2019;9(1):1&#x2013;9. doi: 10.1038/s41598-019-41771-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-41771-4</ArticleId><ArticleId IdType="pmc">PMC6437213</ArticleId><ArticleId IdType="pubmed">30918303</ArticleId></ArticleIdList></Reference><Reference><Citation>Nomura T, Lu R, Pucci ML, Schuster VL. The two-step model of prostaglandin signal termination: in vitro reconstitution with the prostaglandin transporter and prostaglandin 15 dehydrogenase. Mol Pharmacol. 2004;65(4):973&#x2013;978. doi: 10.1124/mol.65.4.973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/mol.65.4.973</ArticleId><ArticleId IdType="pubmed">15044627</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JY, Bian H, Yao Y. Chronic unpredictable mild stress induces parallel reductions of 15-PGDH in the hypothalamus and lungs in rats. Behav Brain Res. 2015;286:278&#x2013;284. doi: 10.1016/j.bbr.2015.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2015.03.013</ArticleId><ArticleId IdType="pubmed">25779923</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, Liu Y, Li K, Miao S, Lv C, Wang C, et al. Regulation of PGE2 pathway during cerebral ischemia reperfusion injury in rat. Cell Mol Neurobiol. 2021;41(7):1483&#x2013;1496. doi: 10.1007/s10571-020-00911-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10571-020-00911-5</ArticleId><ArticleId IdType="pubmed">32621176</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrasco E, Casper D, Werner P. PGE2 receptor EP1 renders dopaminergic neurons selectively vulnerable to low-level oxidative stress and direct PGE2 neurotoxicity. J Neurosci Res. 2007;85(14):3109&#x2013;3117. doi: 10.1002/jnr.21425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.21425</ArticleId><ArticleId IdType="pubmed">17868147</ArticleId></ArticleIdList></Reference><Reference><Citation>Takadera T, Yumoto H, Tozuka Y, Ohyashiki T. Prostaglandin E2 induces caspase-dependent apoptosis in rat cortical cells. Neurosci Lett. 2002;317(2):61&#x2013;64. doi: 10.1016/S0304-3940(01)02449-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(01)02449-1</ArticleId><ArticleId IdType="pubmed">11755240</ArticleId></ArticleIdList></Reference><Reference><Citation>Takadera T, Shiraishi Y, Ohyashiki T. Prostaglandin E2 induced caspase-dependent apoptosis possibly through activation of EP2 receptors in cultured hippocampal neurons. Neurochem Int. 2004;45(5):713&#x2013;719. doi: 10.1016/j.neuint.2004.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2004.02.005</ArticleId><ArticleId IdType="pubmed">15234114</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda-Matsuo Y, Tanji H, Ota A, Hirayama Y, Uematsu S, Akira S, et al. Microsomal prostaglandin e synthase-1 contributes to ischaemic excitotoxicity through prostaglandin E2 EP3 receptors. Br J Pharmacol. 2010;160(4):847&#x2013;859. doi: 10.1111/j.1476-5381.2010.00711.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1476-5381.2010.00711.x</ArticleId><ArticleId IdType="pmc">PMC2935993</ArticleId><ArticleId IdType="pubmed">20590584</ArticleId></ArticleIdList></Reference><Reference><Citation>McCullough L, Wu L, Haughey N, Liang X, Hand T, Wang Q, et al. Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J Neurosci. 2004;24(1):257&#x2013;268. doi: 10.1523/JNEUROSCI.4485-03.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4485-03.2004</ArticleId><ArticleId IdType="pmc">PMC6729582</ArticleId><ArticleId IdType="pubmed">14715958</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilak M, Wu L, Wang Q, Haughey N, Conant K, Hillaire St. C, et al. PGE2 receptors rescue motor neurons in a model of amyotrophic lateral sclerosis. Ann Neurol. 2004;56(2):240&#x2013;248. doi: 10.1002/ana.20179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20179</ArticleId><ArticleId IdType="pubmed">15293276</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad AS, Ahmad M, De Brum-Fernandes AJ, Dor&#xe9; S. Prostaglandin EP4 receptor agonist protects against acute neurotoxicity. Brain Res. 2005;1066(1&#x2013;2):71&#x2013;77. doi: 10.1016/j.brainres.2005.10.068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2005.10.068</ArticleId><ArticleId IdType="pubmed">16360658</ArticleId></ArticleIdList></Reference><Reference><Citation>Cashman NR, Durham HD, Blusztajn JK, Oda K, Tabira T, Shaw IT, et al. Neuroblastoma &#xd7; spinal cord (NSC) hybrid cell lines resemble developing motor neurons. Dev Dyn. 1992;194(3):209&#x2013;221. doi: 10.1002/aja.1001940306.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/aja.1001940306</ArticleId><ArticleId IdType="pubmed">1467557</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier O, B&#xf6;hm J, Dahm M, Br&#xfc;ck S, Beyer C, Johann S, et al. Differentiated NSC-34 motoneuron-like cells as experimental model for cholinergic neurodegeneration. Neurochem Int. 2013;62(8):1029&#x2013;1038. doi: 10.1016/j.neuint.2013.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2013.03.008</ArticleId><ArticleId IdType="pubmed">23562846</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyagishi H, Kosuge Y, Yoneoka Y, Ozone M, Endo M, Osada N, et al. Prostaglandin E2-Induced cell death is mediated by activation of EP2 receptors in motor neuron-like NSC-34 cells. J Pharmacol Sci. 2013;121(4):347&#x2013;350. doi: 10.1254/jphs.12274SC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1254/jphs.12274SC</ArticleId><ArticleId IdType="pubmed">23514786</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang X, Wang Q, Shi J, Lokteva L, Breyer RM, Montine TJ, et al. The prostaglandin E2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis. Ann Neurol. 2008;64(3):304&#x2013;314. doi: 10.1002/ana.21437.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21437</ArticleId><ArticleId IdType="pmc">PMC2766522</ArticleId><ArticleId IdType="pubmed">18825663</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosuge Y, Miyagishi H, Yoneoka Y, Yoneda K, Nango H, Ishige K, et al. Pathophysiological role of prostaglandin E2-induced up-regulation of the EP2 receptor in motor neuron-like NSC-34 cells and lumbar motor neurons in ALS model mice. Neurochem Int. 2018;119:132&#x2013;139. doi: 10.1016/j.neuint.2017.06.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2017.06.013</ArticleId><ArticleId IdType="pubmed">28687401</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma W, Chabot JG, Vercauteren F, Quirion R. Injured nerve-derived COX2/PGE2 contributes to the maintenance of neuropathic pain in aged rats. Neurobiol Aging. 2010;31(7):1227&#x2013;1237. doi: 10.1016/j.neurobiolaging.2008.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2008.08.002</ArticleId><ArticleId IdType="pubmed">18786748</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rez S, Maldonado EN, Aspichueta P, Ochoa B, Chico Y. Differential modulation of prostaglandin receptor mRNA abundance by prostaglandins in primary cultured rat hepatocytes. Mol Cell Biochem. 2004;266(1&#x2013;2):183&#x2013;189. doi: 10.1023/B:MCBI.0000049159.09349.02.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/B:MCBI.0000049159.09349.02</ArticleId><ArticleId IdType="pubmed">15646041</ArticleId></ArticleIdList></Reference><Reference><Citation>Parakh S, Spencer DM, Halloran MA, Soo KY, Atkin JD. Redox regulation in amyotrophic lateral sclerosis. Oxid Med Cell Longev. 2013 doi: 10.1155/2013/408681.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/408681</ArticleId><ArticleId IdType="pmc">PMC3596916</ArticleId><ArticleId IdType="pubmed">23533690</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskarsson B, Gendron TF, Staff NP. Amyotrophic lateral sclerosis: an update for 2018. Mayo Clin Proc. 2018;93(11):1617&#x2013;1628. doi: 10.1016/j.mayocp.2018.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2018.04.007</ArticleId><ArticleId IdType="pubmed">30401437</ArticleId></ArticleIdList></Reference><Reference><Citation>Biswas SK. Does the interdependence between oxidative stress and inflammation explain the antioxidant paradox? Oxid Med Cell Longev. 2016;2016:1&#x2013;9. doi: 10.1155/2016/5698931.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/5698931</ArticleId><ArticleId IdType="pmc">PMC4736408</ArticleId><ArticleId IdType="pubmed">26881031</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensley K, Mhatre M, Mou S, Pye QN, Stewart C, West M, et al. On the relation of oxidative stress to neuroinflammation: lessons learned from the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. Antioxidants Redox Signal. 2006;8(11&#x2013;12):2075&#x2013;2087. doi: 10.1089/ars.2006.8.2075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2006.8.2075</ArticleId><ArticleId IdType="pubmed">17034351</ArticleId></ArticleIdList></Reference><Reference><Citation>Korbecki J, Baranowska-Bosiacka I, Gutowska I, Chlubek D. The effect of reactive oxygen species on the synthesis of prostanoids from arachidonic acid. J Physiol Pharmacol. 2013;64(4):409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">24101387</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi PL, Chen YW, Hsiao LD, Chen YL, Yang CM. Heme oxygenase 1 attenuates interleukin-1&#x3b2;-induced cytosolic phospholipase A2 expression via a decrease in NADPH oxidase/reactive oxygen species/activator protein 1 activation in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum. 2012;64(7):2114&#x2013;2125. doi: 10.1002/art.34371.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34371</ArticleId><ArticleId IdType="pubmed">22231145</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng L, Xia Y, Garcia GE, Hwang D, Wilson CB. Involvement of reactive oxygen intermediates in cyclooxygenase-2 expression induced by interleukin-1, tumor necrosis factor-&#x3b1;, and lipopolysaccharide. J Clin Invest. 1995;95(4):1669&#x2013;1675. doi: 10.1172/JCI117842.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI117842</ArticleId><ArticleId IdType="pmc">PMC295674</ArticleId><ArticleId IdType="pubmed">7706475</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosuge Y, Nango H, Kasai H, Yanagi T, Mawatari T, Nishiyama K, et al. Generation of cellular reactive oxygen species by activation of the EP2 receptor contributes to prostaglandin E2-induced cytotoxicity in motor neuron-like NSC-34 cells. Oxid Med Cell Longev. 2020 doi: 10.1155/2020/6101838.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/6101838</ArticleId><ArticleId IdType="pmc">PMC7201578</ArticleId><ArticleId IdType="pubmed">32411331</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang X, Wang Q, Hand T, Wu L, Breyer RM, Montine TJ, et al. Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer&#x2019;s disease. J Neurosci. 2005;25(44):10180&#x2013;10187. doi: 10.1523/JNEUROSCI.3591-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3591-05.2005</ArticleId><ArticleId IdType="pmc">PMC6725803</ArticleId><ArticleId IdType="pubmed">16267225</ArticleId></ArticleIdList></Reference><Reference><Citation>Gozal E, Metz CJ, Dematteis M, Sachleben LR, Schurr A, Rane MJ. PKA activity exacerbates hypoxia-induced ROS formation and hypoxic injury in PC-12 cells. Toxicol Lett. 2017;279:107&#x2013;114. doi: 10.1016/j.toxlet.2017.07.895.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.toxlet.2017.07.895</ArticleId><ArticleId IdType="pmc">PMC5608019</ArticleId><ArticleId IdType="pubmed">28751209</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrasco E, Werner P, Casper D. Prostaglandin receptor EP2 protects dopaminergic neurons against 6-OHDA-mediated low oxidative stress. Neurosci Lett. 2008;441(1):44&#x2013;49. doi: 10.1016/j.neulet.2008.05.111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2008.05.111</ArticleId><ArticleId IdType="pmc">PMC2570167</ArticleId><ArticleId IdType="pubmed">18597941</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatae N, Sugimoto Y, Ichikawa A. Prostaglandin receptors: advances in the study of EP3 receptor signaling. J Biochem. 2002;131(6):781&#x2013;784. doi: 10.1093/oxfordjournals.jbchem.a003165.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.jbchem.a003165</ArticleId><ArticleId IdType="pubmed">12038972</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosuge Y, Miyagishi H, Shinomiya T, Nishiyama K, Suzuki S, Osada N, et al. Characterization of motor neuron prostaglandin E2 EP3 receptor isoform in a mouse model of amyotrophic lateral sclerosis. Biol Pharm Bull. 2015;38(12):1964&#x2013;1968. doi: 10.1248/bpb.b15-00418.</Citation><ArticleIdList><ArticleId IdType="doi">10.1248/bpb.b15-00418</ArticleId><ArticleId IdType="pubmed">26632188</ArticleId></ArticleIdList></Reference><Reference><Citation>Narita M, Shimamura M, Imai S, Kubota C, Yajima Y, Takagi T, et al. Role of interleukin-1&#x3b2; and tumor necrosis factor-&#x3b1;-dependent expression of cyclooxygenase-2 mRNA in thermal hyperalgesia induced by chronic inflammation in mice. Neuroscience. 2008;152(2):477&#x2013;486. doi: 10.1016/j.neuroscience.2007.10.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2007.10.039</ArticleId><ArticleId IdType="pubmed">18262365</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenneis C, Maier TJ, Schmidt R, Hofacker A, Zulauf L, Jakobsson PJ, et al. Inhibition of prostaglandin E 2 synthesis by SC-560 is independent of cyclooxygenase 1 inhibition. FASEB J. 2006;20(9):1352&#x2013;1360. doi: 10.1096/fj.05-5346com.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.05-5346com</ArticleId><ArticleId IdType="pubmed">16816110</ArticleId></ArticleIdList></Reference><Reference><Citation>de Oliveira ACP, Yousif NM, Bhatia HS, Hermanek J, Huell M, Fiebich BL. Poly(I: C) Increases the expression of mPGES-1 and COX-2 in rat primary microglia. J Neuroinflamm. 2016;13(1):1&#x2013;11. doi: 10.1186/s12974-015-0473-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-015-0473-7</ArticleId><ArticleId IdType="pmc">PMC4717620</ArticleId><ArticleId IdType="pubmed">26780827</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensley K, Abdel-Moaty H, Hunter J, Mhatre M, Mhou S, Nguyen K, et al. Primary glia expressing the G93A-SOD1 mutation present a neuroinflammatory phenotype and provide a cellular system for studies of glial inflammation. J Neuroinflamm. 2006;3:1&#x2013;9. doi: 10.1186/1742-2094-3-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-3-2</ArticleId><ArticleId IdType="pmc">PMC1360663</ArticleId><ArticleId IdType="pubmed">16436205</ArticleId></ArticleIdList></Reference><Reference><Citation>Suk K, Yeou Kim S, Kim H. Regulation of IL-18 production by IFN&#x3b3; and PGE2 in mouse microglial cells: Involvement of NF-kB pathway in the regulatory processes. Immunol Lett. 2001;77(2):79&#x2013;85. doi: 10.1016/S0165-2478(01)00209-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-2478(01)00209-7</ArticleId><ArticleId IdType="pubmed">11377701</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi X, Tai HH. Interleukin-4 up-regulates 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in human lung cancer cells. Exp Cell Res. 2010;316(14):2251&#x2013;2259. doi: 10.1016/j.yexcr.2010.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexcr.2010.06.001</ArticleId><ArticleId IdType="pubmed">20632471</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu P, Genc A, Zhang X, Zhang J, Bazan NG, Chen C. Heterogeneous expression and regulation of hippocampal prostaglandin E2 receptors. J Neurosci Res. 2005;81(6):817&#x2013;826. doi: 10.1002/jnr.20597.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.20597</ArticleId><ArticleId IdType="pubmed">16041798</ArticleId></ArticleIdList></Reference><Reference><Citation>Waschbisch A, Fiebich BL, Akundi RS, Schmitz ML, Hoozemans JJM, Candelario-Jalil E, et al. Interleukin-1 beta-induced expression of the prostaglandin E 2-receptor subtype EP3 in U373 astrocytoma cells depends on protein kinase C and nuclear factor-kappaB. J Neurochem. 2006;96(3):680&#x2013;693. doi: 10.1111/j.1471-4159.2005.03599.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2005.03599.x</ArticleId><ArticleId IdType="pubmed">16405508</ArticleId></ArticleIdList></Reference><Reference><Citation>Fehrenbacher JC, Burkey TH, Nicol GD, Vasko MR. Tumor necrosis factor &#x3b1; and interleukin-1&#x3b2; stimulate the expression of cyclooxygenase II but do not alter prostaglandin E 2 receptor mRNA levels in cultured dorsal root ganglia cells. Pain. 2005;113(1&#x2013;2):113&#x2013;122. doi: 10.1016/j.pain.2004.09.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pain.2004.09.031</ArticleId><ArticleId IdType="pubmed">15621371</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenneis C, Coste O, Altenrath K, Angioni C, Schmidt H, Schuh CD, et al. Anti-inflammatory role of microsomal prostaglandin E synthase-1 in a model of neuroinflammation. J Biol Chem. 2011;286(3):2331&#x2013;2342. doi: 10.1074/jbc.M110.157362.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.157362</ArticleId><ArticleId IdType="pmc">PMC3023527</ArticleId><ArticleId IdType="pubmed">21075851</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodling NS, Wang Q, Priyam PG, Larkin P, Shi J, Johansson JU, et al. Suppression of Alzheimer-associated inflammation by microglial prostaglandin-E2 EP4 receptor signaling. J Neurosci. 2014;34(17):5882&#x2013;5894. doi: 10.1523/JNEUROSCI.0410-14.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0410-14.2014</ArticleId><ArticleId IdType="pmc">PMC3996215</ArticleId><ArticleId IdType="pubmed">24760848</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia Q, Hu Q, Wang H, Yang H, Gao F, Ren H, et al. Induction of COX-2-PGE2 synthesis by activation of the MAPK/ERK pathway contributes to neuronal death triggered by TDP-43-depleted microglia. Cell Death Dis. 2015;6:e1702. doi: 10.1038/cddis.2015.69.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2015.69</ArticleId><ArticleId IdType="pmc">PMC4385945</ArticleId><ArticleId IdType="pubmed">25811799</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov D, Mansfield C, Moussy A, Hermine O. ALS clinical trials review: 20 years of failure Are we any closer to registering a new treatment? Front Aging Neurosci. 2017;9:1&#x2013;11. doi: 10.3389/fnagi.2017.00068.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00068</ArticleId><ArticleId IdType="pmc">PMC5360725</ArticleId><ArticleId IdType="pubmed">28382000</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, Shefner JM, Schoenfeld DA, Zhang H, Andreasson KI, Rothstein JD, et al. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol. 2006;60(1):22&#x2013;31. doi: 10.1002/ana.20903.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20903</ArticleId><ArticleId IdType="pubmed">16802291</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergqvist F, Morgenstern R, Jakobsson PJ. A review on mPGES-1 inhibitors: From preclinical studies to clinical applications. Prostaglandins Other Lipid Mediat. 2020;147:106383. doi: 10.1016/j.prostaglandins.2019.106383.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.prostaglandins.2019.106383</ArticleId><ArticleId IdType="pubmed">31698145</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldshtein H, Muhire A, Petel L&#xe9;gar&#xe9; V, Pushett A, Rotkopf R, Shefner JM, et al. Efficacy of ciprofloxacin/celecoxib combination in zebrafish models of amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2020;7(10):1883&#x2013;1897. doi: 10.1002/acn3.51174.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51174</ArticleId><ArticleId IdType="pmc">PMC7545590</ArticleId><ArticleId IdType="pubmed">32915525</ArticleId></ArticleIdList></Reference><Reference><Citation>Nango H, Kosuge Y. Present state and future perspectives of prostaglandins as a differentiation factor in motor neurons. Cell Mol Neurobiol. 2021;42(7):2097&#x2013;2108. doi: 10.1007/s10571-021-01104-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10571-021-01104-4</ArticleId><ArticleId IdType="pubmed">34032949</ArticleId></ArticleIdList></Reference><Reference><Citation>Nango H, Kosuge Y, Miyagishi H, Sugawa K, Ito Y, Ishige K. Prostaglandin E2 facilitates neurite outgrowth in a motor neuron-like cell line, NSC-34. J Pharmacol Sci. 2017;135(2):64&#x2013;71. doi: 10.1016/j.jphs.2017.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jphs.2017.09.001</ArticleId><ArticleId IdType="pubmed">28966102</ArticleId></ArticleIdList></Reference><Reference><Citation>Nango H, Kosuge Y, Sato M, Shibukawa Y, Aono Y, Saigusa T, et al. Highly efficient conversion of motor neuron-like NSC-34 cells into functional motor neurons by prostaglandin E2. Cells. 2020;9(7):1741. doi: 10.3390/cells9071741.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9071741</ArticleId><ArticleId IdType="pmc">PMC7409148</ArticleId><ArticleId IdType="pubmed">32708195</ArticleId></ArticleIdList></Reference><Reference><Citation>Goncalves MB, Williams EJ, Yip P, Y&#xe1;&#xf1;ez-Mu&#xf1;oz RJ, Williams G, Doherty P. The COX-2 inhibitors, meloxicam and nimesulide, suppress neurogenesis in the adult mouse brain. Br J Pharmacol. 2010;159(5):1118&#x2013;1125. doi: 10.1111/j.1476-5381.2009.00618.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1476-5381.2009.00618.x</ArticleId><ArticleId IdType="pmc">PMC2839269</ArticleId><ArticleId IdType="pubmed">20136845</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong CT, Ussyshkin N, Ahmad E, Rai-Bhogal R, Li H, Crawford DA. Prostaglandin E2 promotes neural proliferation and differentiation and regulates Wnt target gene expression. J Neurosci Res. 2016;94(8):759&#x2013;775. doi: 10.1002/jnr.23759.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.23759</ArticleId><ArticleId IdType="pubmed">27265882</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi L, Ke Y, Luo C, Li B, Gozal D, Kalyanaraman B, et al. Motor neuron degeneration promotes neural progenitor cell proliferation, migration, and neurogenesis in the spinal cords of amyotrophic lateral sclerosis mice. Stem Cells. 2006;24(1):34&#x2013;43. doi: 10.1634/stemcells.2005-0076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1634/stemcells.2005-0076</ArticleId><ArticleId IdType="pmc">PMC1828038</ArticleId><ArticleId IdType="pubmed">16099995</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho L, Luterman JD, Aisen PS, Pasinetti GM, Montine TJ, Morrow JD. Elevated CSF prostaglandin E2 levels in patients with probable AD. Neurology. 2000;55(2):323. doi: 10.1212/WNL.55.2.323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.55.2.323</ArticleId><ArticleId IdType="pubmed">10908926</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattammal MB, Strong R, Lakshmi VM, Chung HD, Stephenson AH. Prostaglandin H synthetase-mediated metabolism of dopamine: implication for Parkinson&#x2019;s disease. J Neurochem. 1995;64(4):1645&#x2013;1654. doi: 10.1046/j.1471-4159.1995.64041645.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1995.64041645.x</ArticleId><ArticleId IdType="pubmed">7891092</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim SH, et al. The amyloid-&#x3b2; pathway in Alzheimer&#x2019;s disease. Mol Psychiatry. 2021;26(10):5481&#x2013;5503. doi: 10.1038/s41380-021-01249-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-021-01249-0</ArticleId><ArticleId IdType="pmc">PMC8758495</ArticleId><ArticleId IdType="pubmed">34456336</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoozemans JJ, Rozemuller AJ, Janssen I, De Groot CJ, Veerhuis R, Eikelenboom P. Cyclooxygenase expression in microglia and neurons in Alzheimer&#x2019;s disease and control brain. Acta Neuropathol. 2001;101(1):2&#x2013;8. doi: 10.1007/s004010000251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s004010000251</ArticleId><ArticleId IdType="pubmed">11194936</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhry UA, Zhuang H, Crain BJ, Dor&#xe9; S. Elevated microsomal prostaglandin-E synthase-1 in Alzheimer&#x2019;s disease. Alzheimers Dement. 2008;4(1):6&#x2013;13. doi: 10.1016/j.jalz.2007.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2007.10.015</ArticleId><ArticleId IdType="pmc">PMC2500207</ArticleId><ArticleId IdType="pubmed">18631945</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhry U, Zhuang H, Dor&#xe9; S. Microsomal prostaglandin E synthase-2: Cellular distribution and expression in Alzheimer&#x2019;s disease. Exp Neurol. 2010;223(2):359&#x2013;365. doi: 10.1016/j.expneurol.2009.07.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2009.07.027</ArticleId><ArticleId IdType="pmc">PMC2864315</ArticleId><ArticleId IdType="pubmed">19664621</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirby LC, Hempelman SR, Berry DL, Mcgeer PL, Kaszniak AW, Cofield M, et al. Clinical trial of indomethacin in Alzheimer&#x2019;s disease. Neurology. 1993;43:1609&#x2013;1611. doi: 10.1212/WNL.43.8.1609.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.43.8.1609</ArticleId><ArticleId IdType="pubmed">8351023</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotilinek LA, Westerman MA, Wang Q, Panizzon K, Lim GP, Simonyi A, et al. Cyclooxygenase-2 inhibition improves amyloid-&#x3b2;-mediated suppression of memory and synaptic plasticity. Brain. 2008;131(3):651&#x2013;664. doi: 10.1093/brain/awn008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awn008</ArticleId><ArticleId IdType="pmc">PMC2628581</ArticleId><ArticleId IdType="pubmed">18292081</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoshino T, Namba T, Takehara M, Nakaya T, Sugimoto Y, Araki W, et al. Prostaglandin E2 stimulates the production of amyloid-&#x3b2; peptides through internalization of the EP4 receptor. J Biol Chem. 2009;284(27):18493&#x2013;18502. doi: 10.1074/jbc.M109.003269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.003269</ArticleId><ArticleId IdType="pmc">PMC2709369</ArticleId><ArticleId IdType="pubmed">19407341</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoshino T, Nakaya T, Homan T, Tanaka KI, Sugimoto Y, Araki W, et al. Involvement of prostaglandin E2 in production of amyloid-&#x3b2; peptides both in vitro and in vivo. J Biol Chem. 2007;282(45):32676&#x2013;32688. doi: 10.1074/jbc.M703087200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M703087200</ArticleId><ArticleId IdType="pubmed">17767011</ArticleId></ArticleIdList></Reference><Reference><Citation>Savonenko A, Munoz P, Melnikova T, Wang Q, Liang X, Breyer RM, et al. Impaired cognition, sensorimotor gating, and hippocampal long-term depression in mice lacking the prostaglandin E2 EP2 receptor. Exp Neurol. 2009;217(1):63&#x2013;73. doi: 10.1016/j.expneurol.2009.01.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2009.01.016</ArticleId><ArticleId IdType="pmc">PMC2720138</ArticleId><ArticleId IdType="pubmed">19416671</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings J, Lee G, Nahed P, Kambar MEZN, Zhong K, Fonseca J, et al. Alzheimer&#x2019;s disease drug development pipeline: 2022. Alzheimer&#x2019;s Dement Transl Res Clin Interv. 2022 doi: 10.1002/trc2.12295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/trc2.12295</ArticleId><ArticleId IdType="pmc">PMC9066743</ArticleId><ArticleId IdType="pubmed">35516416</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabrizi SJ, Ghosh R, Leavitt BR. Huntingtin lowering strategies for disease modification in Huntington&#x2019;s disease. Neuron. 2019;101(5):801&#x2013;819. doi: 10.1016/j.neuron.2019.01.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.01.039</ArticleId><ArticleId IdType="pubmed">30844400</ArticleId></ArticleIdList></Reference><Reference><Citation>Anglada-Huguet M, Xifr&#xf3; X, Giralt A, Zamora-Moratalla A, Mart&#xed;n ED, Alberch J. Prostaglandin E2 EP1 receptor antagonist improves motor deficits and rescues memory decline in R6/1 mouse model of Huntington&#x2019;s disease. Mol Neurobiol. 2014;49(2):784&#x2013;795. doi: 10.1007/s12035-013-8556-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-013-8556-x</ArticleId><ArticleId IdType="pubmed">24198227</ArticleId></ArticleIdList></Reference><Reference><Citation>Anglada-Huguet M, Vidal-Sancho L, Giralt A, Garc&#xed;a-D&#xed;az Barriga G, Xifr&#xf3; X, Alberch J. Prostaglandin E2 EP2 activation reduces memory decline in R6/1 mouse model of Huntington&#x2019;s disease by the induction of BDNF-dependent synaptic plasticity. Neurobiol Dis. 2016;95:22&#x2013;34. doi: 10.1016/j.nbd.2015.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2015.09.001</ArticleId><ArticleId IdType="pubmed">26369879</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloem BR, Okun MS, Klein C. Parkinson&#x2019;s disease. Lancet. 2021;397(10291):2284&#x2013;2303. doi: 10.1016/S0140-6736(21)00218-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00218-X</ArticleId><ArticleId IdType="pubmed">33848468</ArticleId></ArticleIdList></Reference><Reference><Citation>Knott C, Stern G, Wilkin GP. Inflammatory regulators in Parkinson&#x2019;s disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol Cell Neurosci. 2000;16(6):724&#x2013;739. doi: 10.1006/mcne.2000.0914.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/mcne.2000.0914</ArticleId><ArticleId IdType="pubmed">11124893</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T, Pei Z, Zhang W, Liu B, Langenbach R, Lee C, et al. MPP+-induced COX-2 activation and subsequent dopaminergic neurodegeneration. FASEB J. 2005;19(9):1134&#x2013;1136. doi: 10.1096/fj.04-2457fje.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.04-2457fje</ArticleId><ArticleId IdType="pubmed">15845609</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijitruth R, Liu M, Choi DY, Nguyen XV, Hunter RL, Bing G. Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson&#x2019;s disease. J Neuroinflamm. 2006;3:1&#x2013;16. doi: 10.1186/1742-2094-3-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-3-6</ArticleId><ArticleId IdType="pmc">PMC1440849</ArticleId><ArticleId IdType="pubmed">16566823</ArticleId></ArticleIdList></Reference><Reference><Citation>Driver JA, Logroscino G, Lu L, Gaziano JM, Kurth T. Use of non-steroidal anti-inflammatory drugs and risk of Parkinson&#x2019;s disease: nested case-control study. BMJ. 2011;342:d198. doi: 10.1136/bmj.d198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d198</ArticleId><ArticleId IdType="pmc">PMC3023971</ArticleId><ArticleId IdType="pubmed">21252104</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao X, Chen H, Schwarzschild MA, Ascherio A. Use of ibuprofen and risk of Parkinson disease. Neurology. 2011;76(10):863&#x2013;869. doi: 10.1212/WNL.0b013e31820f2d79.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31820f2d79</ArticleId><ArticleId IdType="pmc">PMC3059148</ArticleId><ArticleId IdType="pubmed">21368281</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin J, Shie FS, Liu J, Wang Y, Davis J, Schantz AM, et al. Prostaglandin E2 receptor subtype 2 (EP2) regulates microglial activation and associated neurotoxicity induced by aggregated &#x3b1;-synuclein. J Neuroinflamm. 2007;4:1&#x2013;10. doi: 10.1186/1742-2094-4-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-4-2</ArticleId><ArticleId IdType="pmc">PMC1766347</ArticleId><ArticleId IdType="pubmed">17204153</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med. 2018;378(2):169&#x2013;80. doi: 10.1056/NEJMra1401483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1401483</ArticleId><ArticleId IdType="pmc">PMC6942519</ArticleId><ArticleId IdType="pubmed">29320652</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoub SS, Wood EG, Hassan SU, Bolton C. Cyclooxygenase expression and prostaglandin levels in central nervous system tissues during the course of chronic relapsing experimental autoimmune encephalomyelitis (EAE) Inflamm Res. 2011;60(10):919&#x2013;928. doi: 10.1007/s00011-011-0352-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00011-011-0352-3</ArticleId><ArticleId IdType="pubmed">21667309</ArticleId></ArticleIdList></Reference><Reference><Citation>Reder AT, Thapar M, Sapugay AM, Jensen MA. Prostaglandins and inhibitors of arachidonate metabolism suppress experimental allergic encephalomyelitis. J Neuroimmunol. 1994;54(1&#x2013;2):117&#x2013;127. doi: 10.1016/0165-5728(94)90238-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0165-5728(94)90238-0</ArticleId><ArticleId IdType="pubmed">7523442</ArticleId></ArticleIdList></Reference><Reference><Citation>Kihara Y, Matsushita T, Kita Y, Uematsu S, Akira S, Kira JI, et al. Targeted lipidomics reveals mPGES-1-PGE2 as a therapeutic target for multiple sclerosis. Proc Natl Acad Sci USA. 2009;106(51):21807&#x2013;21812. doi: 10.1073/pnas.0906891106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0906891106</ArticleId><ArticleId IdType="pmc">PMC2789753</ArticleId><ArticleId IdType="pubmed">19995978</ArticleId></ArticleIdList></Reference><Reference><Citation>Esaki Y, Li Y, Sakata D, Yao C, Segi-Nishida E, Matsuoka T, et al. Dual roles of PGE2-EP4 signaling in mouse experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA. 2010;107(27):12233&#x2013;12238. doi: 10.1073/pnas.0915112107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0915112107</ArticleId><ArticleId IdType="pmc">PMC2901475</ArticleId><ArticleId IdType="pubmed">20566843</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>